Skip to main content
Terug
Watch Compare

Alaunos Therapeutics, Inc.

Datakwaliteit: 100%
TCRT
Nasdaq Manufacturing Chemicals
€ 2,89
▲ € 0,04 (1,24%)
Marktkapitalisatie: 6,37 M
Prijs
€ 2,86
Marktkapitalisatie
6,37 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue declined -66,52% annually over 5 years
Negative free cash flow of -2,97 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 16,52%
Capital intensive — 1960,00% of revenue goes to capex

Groei

Revenue Growth (5Y)
-66,52%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)-50,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-129,21%
Onder sectorgemiddelde (-53,47%)
ROIC-103,27%
Net Margin-83520,00%
Op. Margin-84500,00%

Veiligheid

Debt / Equity
N/A
Current Ratio2,92
Interest CoverageN/A

Waardering

PE (TTM)
-1,53
Onder sectorgemiddelde (-1,48)
P/B Ratio2,27
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -1,5 -1,5
P/B 2,3 1,6
ROE % -129,2 -53,5
Net Margin % -83520,0 -41,5
Rev Growth 5Y % -66,5 1,8
D/E — 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Geen toekomstige schattingen beschikbaar

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42023 -€ 4,50 -€ 17,09 -279,9%
Q32023 -€ 5,25 -€ 4,41 +16,0%
Q22023 -€ 6,75 -€ 6,00 +11,1%
Q12023 -€ 6,60 -€ 6,00 +9,1%

All Fundamental Metrics
Growth
Revenue Growth (1Y) -50,00% Revenue Growth (3Y) 0,00%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -66,52% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 5.000,0 Net Income (TTM) -4,18 M
ROE -129,21% ROA -98,74%
Gross Margin N/A Operating Margin -84500,00%
Net Margin -83520,00% Free Cash Flow (TTM) -2,97 M
ROIC -103,27% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2,92
Interest Coverage N/A Asset Turnover 0,00
Working Capital 1,76 M Tangible Book Value 2,80 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,53 Forward P/E N/A
P/B Ratio 2,27 P/S Ratio 1274,15
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -46,57%
Market Cap 6,37 M Enterprise Value 4,43 M
Per Share
EPS (Diluted TTM) -2,20 Revenue / Share 0,00
FCF / Share -1,33 OCF / Share -1,29
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1960,00% FCF Conversion 71,05%
SBC-Adj. FCF -3,60 M Growth Momentum 16,52

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 5.000,0 10.000,0 5.000,0 2,92 M 398.000,0
Net Income -4,18 M -4,68 M -35,14 M -37,73 M -78,75 M
EPS (Diluted) -2,20 -2,92 -2,20 -0,17 —
Gross Profit — — — — —
Operating Income -4,23 M -4,81 M -34,27 M -35,11 M -77,55 M
EBITDA — — — — —
R&D Expenses 1,36 M 362.000,0 16,28 M 25,02 M 49,64 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — 1,90 M 1,92 M 3,15 M 1,20 M
Income Tax 0,0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2,97 M 2,76 M 8,26 M 64,94 M 94,87 M
Total Liabilities 813.000,0 692.000,0 1,96 M 26,38 M 36,81 M
Shareholders' Equity 2,15 M 2,06 M 6,31 M 38,56 M 58,06 M
Total Debt — 0,0 0,0 0,0 16,25 M
Cash & Equivalents 1,39 M 1,09 M 6,06 M 39,06 M 76,05 M
Current Assets 1,99 M 2,76 M 8,26 M 53,80 M 78,83 M
Current Liabilities 813.000,0 692.000,0 1,96 M 24,17 M 16,04 M